Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
For the research team, the question was: “Can we turn something that is good for the cancer into something that will kill [it]?”
New data strongly suggest that axi-cel, as this CAR T-cell therapy is often called, can offer real hope for these lymphoma patients.
The experimental drug motixafortide helps blood-forming stem cells move from a person’s bone marrow into the bloodstream.
A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.
A five-year effort by Penn’s Abramson Cancer Center increased clinical trial enrollment of Black patients with cancer from 12% to 24%.
Cancer Health blogger Dann Wonser says the key to his 14-year survival with non-small-cell lung cancer is his wife, Genevieve de Renne.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
New targeted therapies and immunotherapies can lead to better treatment outcomes.
Effort aims to help dying patients gain legal access to psilocybin — the mind-altering compound found in so-called magic mushrooms.
After being diagnosed with internal melanoma, Gail decided to undergo a clinical trial of an experimental combination.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.